XML 11 R2.htm IDEA: XBRL DOCUMENT
v3.25.1

Pay vs Performance Disclosure - USD ($) | 12 Months Ended
--- | ---
Dec. 31, 2024 | Dec. 31, 2023 | Dec. 31, 2022
Pay vs Performance Disclosure |  |  |
Pay vs Performance Disclosure, Table | As required by Section 953(a) of the Dodd-Frank Wall Street Reform and Consumer Protection Act, and Item 402(v) of Regulation S-K, we are providing the following information about the relationship between executive “compensation actually paid” and certain financial performance of our Company. ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ |  | ​ | ​ |  | ​ | ​ |  | Average |  | ​ | ​ |  | Value of Initial |  | ​ | ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | Summary | ​ | Average | ​ | Fixed $100 | ​ | ​ | ​
​ | ​ | Summary | ​ | ​ | ​ | ​ | Compensation | ​ | Compensation | ​ | Investment Based | ​ | ​ | ​
​ | ​ | Compensation | ​ | Compensation | ​ | Table Total for | ​ | Actually Paid to | ​ | On Total | ​ | ​ | ​
​ | ​ | Table Total for | ​ | Actually paid to |  | Non-CEO NEOs |  | Non-CEO NEOs |  | Stockholder | ​ | ​ | ​
Year | ​ | Mr. Bashan (1) | ​ | Mr. Bashan (2) |  | (3) | ​ | (4) |  | Return (5) | ​ | Net Income (6)
2024 | ​ | $ | 1,527,792 | ​ | $ | 524,655 | ​ | $ | 749,713 | ​ | $ | 488,529 | ​ | $ | 105.62 | ​ | $ | 2,932,000
2023 | ​ | $ | 2,684,941 | ​ | $ | 3,186,324 | ​ | $ | 902,702 | ​ | $ | 1,094,613 | ​ |  | 129.93 | ​ | $ | 8,312,000
2022 | ​ | $ | 1,468,296 | ​ | $ | 1,899,221 | ​ | $ | 795,773 | ​ | $ | 1,056,338 | ​ |  | 37.74 | ​ | $ | (14,927,000)
(1)The dollar amounts reported are the amounts reported in the “Total” column of the Summary Compensation Table for Mr. Bashan, our President and Chief Executive Officer. (2)The dollar amounts reported represent the amount of “compensation actually paid” to Mr. Bashan, as computed in accordance with SEC regulations. The dollar amounts do not reflect the actual amount of compensation earned by or paid to Mr. Bashan during the applicable year. In accordance with SEC regulations, the following adjustments were made to Mr. Bashan’s total compensation to determine the compensation actually paid: ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ |  | ​ | ​ |  | Less: Summary |  | ​ | ​ |  | ​ | ​
​ | ​ | Summary | ​ | Compensation | ​ | ​ | ​ | ​ | Equals:
​ | ​ | Compensation | ​ | Table Reported | ​ | ​ | ​ | ​ | Compensation
​ | ​ | Table Total for | ​ | Value of Equity | ​ | Plus: Equity Award | ​ | Actually paid to
Year | ​ | Mr. Bashan | ​ | Awards (a) | ​ | Adjustments (b) | ​ | Mr. Bashan
2024 | ​ | $ | 1,527,792 | ​ | $ | 1,037,121 | ​ | $ | 33,984 | ​ | $ | 524,655
2023 | ​ | $ | 2,684,941 | ​ | $ | 1,308,118 | ​ | $ | 1,809,501 | ​ | $ | 3,186,324
2022 | ​ | $ | 1,468,296 | ​ | $ | 995,140 | ​ | $ | 1,426,065 | ​ | $ | 1,899,221
(a)Represents the aggregate grant-date fair value of equity awards as reported in the “Stock Awards” and “Option Awards” columns in the Summary Compensation Table for the applicable year. (b)The equity award adjustments for each applicable year were as set forth in the table below. The valuation assumptions used to calculate fair values did not materially differ from those disclosed at the time of grant. The amounts deducted or added in calculating the equity award adjustments are as follows: ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ |  | ​ | ​ |  | ​ | ​ |  | ​ | ​ |  | ​ | ​ |  | Fair Value |  | ​ | ​ |  | ​ | ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | at the End | ​ | Value of | ​ | ​ | ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | of the Prior | ​ | Dividend | ​ | ​ | ​
​ | ​ | ​ | ​ | ​ | Year over Year | ​ | Year End | ​ | ​ | ​ | ​ | Year of | ​ | Equivalents | ​ | ​ | ​
​ | ​ | ​ | ​ | ​ | Change in fair | ​ | Fair Value | ​ | Year over Year | ​ | Equity | ​ | Accrued or | ​ | ​ | ​
​ | ​ | ​ | ​ | ​ | Value of | ​ | of Vested | ​ | Change in Fair | ​ | Awards that | ​ | other Earnings | ​ | ​ | ​
​ | ​ | Year End Fair | ​ | Outstanding | ​ | Equity | ​ | Value of Equity | ​ | Failed to | ​ | Paid on Stock | ​ | ​ | ​
​ | ​ | Value of Unvested | ​ | and Unvested | ​ | Awards | ​ | Awards Granted | ​ | meet | ​ | Awards not | ​ | ​ | ​
​ | ​ | Equity Awards | ​ | Equity Awards | ​ | Granted in | ​ | in Prior Years | ​ | Vesting | ​ | Otherwise | ​ | Total Equity
​ | ​ | Granted in the | ​ | Granted in | ​ | the Covered | ​ | that Vested in the | ​ | Conditions | ​ | Reflected in | ​ | Award
Year | ​ | Covered Year | ​ | prior Years | ​ | Year | ​ | Year | ​ | in the Year | ​ | Fair Value | ​ | Adjustments
2024 | ​ | $ | — | ​ | $ | 5,049 | ​ | $ | 329,950 | ​ | $ | (301,015) | ​ | $ | — | ​ | $ | — | ​ | $ | 33,984
2023 | ​ | $ | 934,501 | ​ | $ | 210,735 | ​ | $ | 505,750 | ​ | $ | 158,515 | ​ | $ | — | ​ | $ | — | ​ | $ | 1,809,501
2022 | ​ | $ | 717,652 | ​ | $ | 110,664 | ​ | $ | 566,768 | ​ | $ | 30,981 | ​ | $ | — | ​ | $ | — | ​ | $ | 1,426,065
(3)The dollar amounts reported represent the average of the amounts reported for our Named Executive Officers as a group (excluding our CEO) in the “Total” column of the Summary Compensation Table in each applicable year. The Named Executive Officers included for purposes of calculating the average amounts are Mr. Rubin and Mr. Naos. (4)The dollar amounts reported represent the average amount of “compensation actually paid” to the Named Executive Officers identified in footnote 3, as computed in accordance with SEC regulations. The dollar amounts do not reflect the actual amount of compensation earned by or paid to the Named Executive Officers during the applicable year. In accordance with the SEC regulations, the following adjustments were made to average total compensation for the Named Executive Officers for each year to determine the compensation actually paid: ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ |  | Average Reported |  | ​ | ​ |  | ​ | ​ |  | ​ | ​
​ | ​ | Summary | ​ | Less: Summary | ​ | ​ | ​ | ​ | Equals: Average
​ | ​ | Compensation | ​ | Compensation Table Average | ​ | Plus: Average | ​ | Compensation
​ | ​ | Table Total for | ​ | Reported Value of | ​ | Equity Award | ​ | Actually Paid to
Year |  | Other NEOs |  | Equity Awards |  | Adjustments (a) |  | ​ | Other NEOs
2024 | ​ | $ | 749,713 | ​ | $ | 293,799 | ​ | $ | 32,616 | ​ | $ | 488,529
2023 | ​ | $ | 902,702 | ​ | $ | 302,403 | ​ | $ | 494,314 | ​ | $ | 1,094,613
2022 | ​ | $ | 795,773 | ​ | $ | 183,933 | ​ | $ | 444,498 | ​ | $ | 1,056,338
(a) | The amounts deducted or added in calculating the total average equity award adjustments are as follows:
​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ |  | ​ | ​ |  | ​ | ​ |  | ​ | ​ |  | Year over |  | Fair Value at |  | Average Value |  | ​ | ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | Average Year | ​ | Year Average | ​ | the End of | ​ | of Dividend | ​ | ​ | ​
​ | ​ | ​ | ​ | ​ | Year over Year | ​ | End Fair | ​ | Change in | ​ | the Prior | ​ | Equivalents | ​ | ​ | ​
​ | ​ | ​ | ​ | ​ | Average | ​ | Value of | ​ | Fair Value of | ​ | Year of | ​ | Accrued or | ​ | ​ | ​
​ | ​ | Average Year End | ​ | Change in fair | ​ | Vested | ​ | Equity | ​ | Equity | ​ | other Earnings | ​ | ​ | ​
​ | ​ | Fair Value of | ​ | Value of | ​ | Equity | ​ | Awards | ​ | Awards that | ​ | Paid on Stock | ​ | ​ | ​
​ | ​ | Unvested Equity | ​ | Outstanding and | ​ | Awards | ​ | Granted in | ​ | Failed to | ​ | Awards not | ​ | ​ | ​
​ | ​ | Awards Granted | ​ | Unvested Equity Awards | ​ | Granted in | ​ | Prior Years | ​ | meet Vesting | ​ | Otherwise | ​ | Total Average
​ | ​ | in the Covered | ​ | Granted in prior | ​ | the Covered | ​ | that Vested in | ​ | Conditions in | ​ | Reflected in | ​ | Equity Award
Year |  | Year |  | Years |  | Year |  | the Year |  | the Year |  | Fair Value |  | Adjustments
2024 | ​ | $ | 66,865 | ​ | $ | 3,326 | ​ | $ | 55,513 | ​ | $ | (93,089) | ​ | $ | — | ​ | $ | — | ​ | $ | 32,616
2023 | ​ | $ | 317,561 | ​ | $ | 89,197 | ​ | $ | 22,868 | ​ | $ | 64,688 | ​ | $ | — | ​ | $ | — | ​ | $ | 494,314
2022 | ​ | $ | 330,120 | ​ | $ | 36,648 | ​ | $ | 67,913 | ​ | $ | 9,817 | ​ | $ | — | ​ | $ | — | ​ | $ | 444,498
(5)Cumulative TSR is the value of a $100 investment in our common stock calculated by dividing the difference between the per share price of our common stock at the end of each year shown and the beginning of the measurement period by the per share price of our common stock at the beginning of the measurement period. (6)The dollar amounts reported represent the amount of net income reflected in our Consolidated Statements of Income included in our Annual Report on Form 10-K for the applicable fiscal year. |  |
Named Executive Officers, Footnote | (1)The dollar amounts reported are the amounts reported in the “Total” column of the Summary Compensation Table for Mr. Bashan, our President and Chief Executive Officer. (3)The dollar amounts reported represent the average of the amounts reported for our Named Executive Officers as a group (excluding our CEO) in the “Total” column of the Summary Compensation Table in each applicable year. The Named Executive Officers included for purposes of calculating the average amounts are Mr. Rubin and Mr. Naos. |  |
PEO Total Compensation Amount | $ 1,527,792 | $ 2,684,941 | $ 1,468,296
PEO Actually Paid Compensation Amount | $ 524,655 | 3,186,324 | 1,899,221
Adjustment To PEO Compensation, Footnote | (2)The dollar amounts reported represent the amount of “compensation actually paid” to Mr. Bashan, as computed in accordance with SEC regulations. The dollar amounts do not reflect the actual amount of compensation earned by or paid to Mr. Bashan during the applicable year. In accordance with SEC regulations, the following adjustments were made to Mr. Bashan’s total compensation to determine the compensation actually paid: ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ |  | ​ | ​ |  | Less: Summary |  | ​ | ​ |  | ​ | ​
​ | ​ | Summary | ​ | Compensation | ​ | ​ | ​ | ​ | Equals:
​ | ​ | Compensation | ​ | Table Reported | ​ | ​ | ​ | ​ | Compensation
​ | ​ | Table Total for | ​ | Value of Equity | ​ | Plus: Equity Award | ​ | Actually paid to
Year | ​ | Mr. Bashan | ​ | Awards (a) | ​ | Adjustments (b) | ​ | Mr. Bashan
2024 | ​ | $ | 1,527,792 | ​ | $ | 1,037,121 | ​ | $ | 33,984 | ​ | $ | 524,655
2023 | ​ | $ | 2,684,941 | ​ | $ | 1,308,118 | ​ | $ | 1,809,501 | ​ | $ | 3,186,324
2022 | ​ | $ | 1,468,296 | ​ | $ | 995,140 | ​ | $ | 1,426,065 | ​ | $ | 1,899,221
(a)Represents the aggregate grant-date fair value of equity awards as reported in the “Stock Awards” and “Option Awards” columns in the Summary Compensation Table for the applicable year. (b)The equity award adjustments for each applicable year were as set forth in the table below. The valuation assumptions used to calculate fair values did not materially differ from those disclosed at the time of grant. The amounts deducted or added in calculating the equity award adjustments are as follows: ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ |  | ​ | ​ |  | ​ | ​ |  | ​ | ​ |  | ​ | ​ |  | Fair Value |  | ​ | ​ |  | ​ | ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | at the End | ​ | Value of | ​ | ​ | ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | of the Prior | ​ | Dividend | ​ | ​ | ​
​ | ​ | ​ | ​ | ​ | Year over Year | ​ | Year End | ​ | ​ | ​ | ​ | Year of | ​ | Equivalents | ​ | ​ | ​
​ | ​ | ​ | ​ | ​ | Change in fair | ​ | Fair Value | ​ | Year over Year | ​ | Equity | ​ | Accrued or | ​ | ​ | ​
​ | ​ | ​ | ​ | ​ | Value of | ​ | of Vested | ​ | Change in Fair | ​ | Awards that | ​ | other Earnings | ​ | ​ | ​
​ | ​ | Year End Fair | ​ | Outstanding | ​ | Equity | ​ | Value of Equity | ​ | Failed to | ​ | Paid on Stock | ​ | ​ | ​
​ | ​ | Value of Unvested | ​ | and Unvested | ​ | Awards | ​ | Awards Granted | ​ | meet | ​ | Awards not | ​ | ​ | ​
​ | ​ | Equity Awards | ​ | Equity Awards | ​ | Granted in | ​ | in Prior Years | ​ | Vesting | ​ | Otherwise | ​ | Total Equity
​ | ​ | Granted in the | ​ | Granted in | ​ | the Covered | ​ | that Vested in the | ​ | Conditions | ​ | Reflected in | ​ | Award
Year | ​ | Covered Year | ​ | prior Years | ​ | Year | ​ | Year | ​ | in the Year | ​ | Fair Value | ​ | Adjustments
2024 | ​ | $ | — | ​ | $ | 5,049 | ​ | $ | 329,950 | ​ | $ | (301,015) | ​ | $ | — | ​ | $ | — | ​ | $ | 33,984
2023 | ​ | $ | 934,501 | ​ | $ | 210,735 | ​ | $ | 505,750 | ​ | $ | 158,515 | ​ | $ | — | ​ | $ | — | ​ | $ | 1,809,501
2022 | ​ | $ | 717,652 | ​ | $ | 110,664 | ​ | $ | 566,768 | ​ | $ | 30,981 | ​ | $ | — | ​ | $ | — | ​ | $ | 1,426,065
Non-PEO NEO Average Total Compensation Amount | $ 749,713 | 902,702 | 795,773
Non-PEO NEO Average Compensation Actually Paid Amount | $ 488,529 | 1,094,613 | 1,056,338
Adjustment to Non-PEO NEO Compensation Footnote | ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ |  | Average Reported |  | ​ | ​ |  | ​ | ​ |  | ​ | ​
​ | ​ | Summary | ​ | Less: Summary | ​ | ​ | ​ | ​ | Equals: Average
​ | ​ | Compensation | ​ | Compensation Table Average | ​ | Plus: Average | ​ | Compensation
​ | ​ | Table Total for | ​ | Reported Value of | ​ | Equity Award | ​ | Actually Paid to
Year |  | Other NEOs |  | Equity Awards |  | Adjustments (a) |  | ​ | Other NEOs
2024 | ​ | $ | 749,713 | ​ | $ | 293,799 | ​ | $ | 32,616 | ​ | $ | 488,529
2023 | ​ | $ | 902,702 | ​ | $ | 302,403 | ​ | $ | 494,314 | ​ | $ | 1,094,613
2022 | ​ | $ | 795,773 | ​ | $ | 183,933 | ​ | $ | 444,498 | ​ | $ | 1,056,338
(a) | The amounts deducted or added in calculating the total average equity award adjustments are as follows:
​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ |  | ​ | ​ |  | ​ | ​ |  | ​ | ​ |  | Year over |  | Fair Value at |  | Average Value |  | ​ | ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | Average Year | ​ | Year Average | ​ | the End of | ​ | of Dividend | ​ | ​ | ​
​ | ​ | ​ | ​ | ​ | Year over Year | ​ | End Fair | ​ | Change in | ​ | the Prior | ​ | Equivalents | ​ | ​ | ​
​ | ​ | ​ | ​ | ​ | Average | ​ | Value of | ​ | Fair Value of | ​ | Year of | ​ | Accrued or | ​ | ​ | ​
​ | ​ | Average Year End | ​ | Change in fair | ​ | Vested | ​ | Equity | ​ | Equity | ​ | other Earnings | ​ | ​ | ​
​ | ​ | Fair Value of | ​ | Value of | ​ | Equity | ​ | Awards | ​ | Awards that | ​ | Paid on Stock | ​ | ​ | ​
​ | ​ | Unvested Equity | ​ | Outstanding and | ​ | Awards | ​ | Granted in | ​ | Failed to | ​ | Awards not | ​ | ​ | ​
​ | ​ | Awards Granted | ​ | Unvested Equity Awards | ​ | Granted in | ​ | Prior Years | ​ | meet Vesting | ​ | Otherwise | ​ | Total Average
​ | ​ | in the Covered | ​ | Granted in prior | ​ | the Covered | ​ | that Vested in | ​ | Conditions in | ​ | Reflected in | ​ | Equity Award
Year |  | Year |  | Years |  | Year |  | the Year |  | the Year |  | Fair Value |  | Adjustments
2024 | ​ | $ | 66,865 | ​ | $ | 3,326 | ​ | $ | 55,513 | ​ | $ | (93,089) | ​ | $ | — | ​ | $ | — | ​ | $ | 32,616
2023 | ​ | $ | 317,561 | ​ | $ | 89,197 | ​ | $ | 22,868 | ​ | $ | 64,688 | ​ | $ | — | ​ | $ | — | ​ | $ | 494,314
2022 | ​ | $ | 330,120 | ​ | $ | 36,648 | ​ | $ | 67,913 | ​ | $ | 9,817 | ​ | $ | — | ​ | $ | — | ​ | $ | 444,498
Compensation Actually Paid vs. Total Shareholder Return | Compensation actually paid to Mr. Bashan during the year ended December 31, 2024 was approximately $0.5 million, a decrease of approximately $2.7 million from approximately $3.2 million for the year ended December 31, 2023. Average compensation actually paid to our Non-CEO Named Executive Officers for the years ended December 31, 2024 was approximately $0.5 million, a decrease of approximately $0.6 million from approximately $1.1 million for the year ended December 31, 2023. For the year ended December 31, 2024, our TSR was $105.62, a decrease of 18.7%, compared to TSR of $129.93 for the year ended December 31, 2023. Our net income for the year ended December 31, 2024 was $2.9 million compared to net income of $8.3 million over the same period in 2023. Compensation actually paid to Mr. Bashan and to our Non-CEO Named Executive Officers as a group is not directly correlated with our TSR or our net income (loss) over the three years presented in the above tables. Over the course of fiscal year 2022 and the first half of fiscal year 2023, we focused primarily on the clinical and regulatory development and approval of pegunigalsidase alfa. During the second half of fiscal year 2023 through fiscal year 2024, we shifted our focus to the support of our commercial partner’s launch efforts post approval, and redirecting our R&D and clinical resources towards the strengthening of our pipeline of product candidates, including but not limited to, our leading drug candidate, PRX-115 (pegylated Uricase for the potential treatment of uncontrolled Gout). Accordingly, TSR and net income (loss), as performance measures, are not directly correlated to our executive compensation determinations. As increases in the market price of our common stock correspond to increases in the fair market value of our equity grants, the calculation of compensation actually paid with respect to equity grants held by Mr. Bashan and to our Non-CEO Named Executive Officers increases in a like manner. In the year ended December 31, 2023, given the approval of pegunigalsidase alfa for adult patients with Fabry disease by both the FDA and the EMA, the advancement in the clinical development of our PRX-115 drug candidate and strengthening of our Company’s liquidity and cash position, the Compensation Committee of our Board of Directors elected to award to Mr. Bashan and to our Non-CEO Named Executive Officers, as well as other officers and employees of our Company, an annual cash bonus and a one-time special cash bonus for such positive achievements. |  |
Compensation Actually Paid vs. Net Income | Compensation actually paid to Mr. Bashan during the year ended December 31, 2024 was approximately $0.5 million, a decrease of approximately $2.7 million from approximately $3.2 million for the year ended December 31, 2023. Average compensation actually paid to our Non-CEO Named Executive Officers for the years ended December 31, 2024 was approximately $0.5 million, a decrease of approximately $0.6 million from approximately $1.1 million for the year ended December 31, 2023. For the year ended December 31, 2024, our TSR was $105.62, a decrease of 18.7%, compared to TSR of $129.93 for the year ended December 31, 2023. Our net income for the year ended December 31, 2024 was $2.9 million compared to net income of $8.3 million over the same period in 2023. Compensation actually paid to Mr. Bashan and to our Non-CEO Named Executive Officers as a group is not directly correlated with our TSR or our net income (loss) over the three years presented in the above tables. Over the course of fiscal year 2022 and the first half of fiscal year 2023, we focused primarily on the clinical and regulatory development and approval of pegunigalsidase alfa. During the second half of fiscal year 2023 through fiscal year 2024, we shifted our focus to the support of our commercial partner’s launch efforts post approval, and redirecting our R&D and clinical resources towards the strengthening of our pipeline of product candidates, including but not limited to, our leading drug candidate, PRX-115 (pegylated Uricase for the potential treatment of uncontrolled Gout). Accordingly, TSR and net income (loss), as performance measures, are not directly correlated to our executive compensation determinations. As increases in the market price of our common stock correspond to increases in the fair market value of our equity grants, the calculation of compensation actually paid with respect to equity grants held by Mr. Bashan and to our Non-CEO Named Executive Officers increases in a like manner. In the year ended December 31, 2023, given the approval of pegunigalsidase alfa for adult patients with Fabry disease by both the FDA and the EMA, the advancement in the clinical development of our PRX-115 drug candidate and strengthening of our Company’s liquidity and cash position, the Compensation Committee of our Board of Directors elected to award to Mr. Bashan and to our Non-CEO Named Executive Officers, as well as other officers and employees of our Company, an annual cash bonus and a one-time special cash bonus for such positive achievements. |  |
Total Shareholder Return Amount | $ 105.62 | 129.93 | 37.74
Net Income (Loss) | $ 2,932,000 | 8,312,000 | (14,927,000)
PEO Name | Mr. Bashan |  |
Equity Awards Adjustments, Footnote | (b)The equity award adjustments for each applicable year were as set forth in the table below. The valuation assumptions used to calculate fair values did not materially differ from those disclosed at the time of grant. The amounts deducted or added in calculating the equity award adjustments are as follows: ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ |  | ​ | ​ |  | ​ | ​ |  | ​ | ​ |  | ​ | ​ |  | Fair Value |  | ​ | ​ |  | ​ | ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | at the End | ​ | Value of | ​ | ​ | ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | of the Prior | ​ | Dividend | ​ | ​ | ​
​ | ​ | ​ | ​ | ​ | Year over Year | ​ | Year End | ​ | ​ | ​ | ​ | Year of | ​ | Equivalents | ​ | ​ | ​
​ | ​ | ​ | ​ | ​ | Change in fair | ​ | Fair Value | ​ | Year over Year | ​ | Equity | ​ | Accrued or | ​ | ​ | ​
​ | ​ | ​ | ​ | ​ | Value of | ​ | of Vested | ​ | Change in Fair | ​ | Awards that | ​ | other Earnings | ​ | ​ | ​
​ | ​ | Year End Fair | ​ | Outstanding | ​ | Equity | ​ | Value of Equity | ​ | Failed to | ​ | Paid on Stock | ​ | ​ | ​
​ | ​ | Value of Unvested | ​ | and Unvested | ​ | Awards | ​ | Awards Granted | ​ | meet | ​ | Awards not | ​ | ​ | ​
​ | ​ | Equity Awards | ​ | Equity Awards | ​ | Granted in | ​ | in Prior Years | ​ | Vesting | ​ | Otherwise | ​ | Total Equity
​ | ​ | Granted in the | ​ | Granted in | ​ | the Covered | ​ | that Vested in the | ​ | Conditions | ​ | Reflected in | ​ | Award
Year | ​ | Covered Year | ​ | prior Years | ​ | Year | ​ | Year | ​ | in the Year | ​ | Fair Value | ​ | Adjustments
2024 | ​ | $ | — | ​ | $ | 5,049 | ​ | $ | 329,950 | ​ | $ | (301,015) | ​ | $ | — | ​ | $ | — | ​ | $ | 33,984
2023 | ​ | $ | 934,501 | ​ | $ | 210,735 | ​ | $ | 505,750 | ​ | $ | 158,515 | ​ | $ | — | ​ | $ | — | ​ | $ | 1,809,501
2022 | ​ | $ | 717,652 | ​ | $ | 110,664 | ​ | $ | 566,768 | ​ | $ | 30,981 | ​ | $ | — | ​ | $ | — | ​ | $ | 1,426,065
(a) | The amounts deducted or added in calculating the total average equity award adjustments are as follows:
​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ |  | ​ | ​ |  | ​ | ​ |  | ​ | ​ |  | Year over |  | Fair Value at |  | Average Value |  | ​ | ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | Average Year | ​ | Year Average | ​ | the End of | ​ | of Dividend | ​ | ​ | ​
​ | ​ | ​ | ​ | ​ | Year over Year | ​ | End Fair | ​ | Change in | ​ | the Prior | ​ | Equivalents | ​ | ​ | ​
​ | ​ | ​ | ​ | ​ | Average | ​ | Value of | ​ | Fair Value of | ​ | Year of | ​ | Accrued or | ​ | ​ | ​
​ | ​ | Average Year End | ​ | Change in fair | ​ | Vested | ​ | Equity | ​ | Equity | ​ | other Earnings | ​ | ​ | ​
​ | ​ | Fair Value of | ​ | Value of | ​ | Equity | ​ | Awards | ​ | Awards that | ​ | Paid on Stock | ​ | ​ | ​
​ | ​ | Unvested Equity | ​ | Outstanding and | ​ | Awards | ​ | Granted in | ​ | Failed to | ​ | Awards not | ​ | ​ | ​
​ | ​ | Awards Granted | ​ | Unvested Equity Awards | ​ | Granted in | ​ | Prior Years | ​ | meet Vesting | ​ | Otherwise | ​ | Total Average
​ | ​ | in the Covered | ​ | Granted in prior | ​ | the Covered | ​ | that Vested in | ​ | Conditions in | ​ | Reflected in | ​ | Equity Award
Year |  | Year |  | Years |  | Year |  | the Year |  | the Year |  | Fair Value |  | Adjustments
2024 | ​ | $ | 66,865 | ​ | $ | 3,326 | ​ | $ | 55,513 | ​ | $ | (93,089) | ​ | $ | — | ​ | $ | — | ​ | $ | 32,616
2023 | ​ | $ | 317,561 | ​ | $ | 89,197 | ​ | $ | 22,868 | ​ | $ | 64,688 | ​ | $ | — | ​ | $ | — | ​ | $ | 494,314
2022 | ​ | $ | 330,120 | ​ | $ | 36,648 | ​ | $ | 67,913 | ​ | $ | 9,817 | ​ | $ | — | ​ | $ | — | ​ | $ | 444,498
PEO | Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table |  |  |
Pay vs Performance Disclosure |  |  |
Adjustment to Compensation, Amount | $ (1,037,121) | (1,308,118) | (995,140)
PEO | Equity Awards Adjustments, Excluding Value Reported in Compensation Table |  |  |
Pay vs Performance Disclosure |  |  |
Adjustment to Compensation, Amount | 33,984 | 1,809,501 | 1,426,065
PEO | Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested |  |  |
Pay vs Performance Disclosure |  |  |
Adjustment to Compensation, Amount |  | 934,501 | 717,652
PEO | Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested |  |  |
Pay vs Performance Disclosure |  |  |
Adjustment to Compensation, Amount | 5,049 | 210,735 | 110,664
PEO | Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year |  |  |
Pay vs Performance Disclosure |  |  |
Adjustment to Compensation, Amount | 329,950 | 505,750 | 566,768
PEO | Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year |  |  |
Pay vs Performance Disclosure |  |  |
Adjustment to Compensation, Amount | (301,015) | 158,515 | 30,981
Non-PEO NEO | Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table |  |  |
Pay vs Performance Disclosure |  |  |
Adjustment to Compensation, Amount | (293,799) | (302,403) | (183,933)
Non-PEO NEO | Equity Awards Adjustments, Excluding Value Reported in Compensation Table |  |  |
Pay vs Performance Disclosure |  |  |
Adjustment to Compensation, Amount | 32,616 | 494,314 | 444,498
Non-PEO NEO | Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested |  |  |
Pay vs Performance Disclosure |  |  |
Adjustment to Compensation, Amount | 66,865 | 317,561 | 330,120
Non-PEO NEO | Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested |  |  |
Pay vs Performance Disclosure |  |  |
Adjustment to Compensation, Amount | 3,326 | 89,197 | 36,648
Non-PEO NEO | Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year |  |  |
Pay vs Performance Disclosure |  |  |
Adjustment to Compensation, Amount | 55,513 | 22,868 | 67,913
Non-PEO NEO | Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year |  |  |
Pay vs Performance Disclosure |  |  |
Adjustment to Compensation, Amount | $ (93,089) | $ 64,688 | $ 9,817

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 3 + Details
Name: | ecd_AdjToCompAmt
Namespace Prefix: | ecd_
Data Type: | xbrli:monetaryItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 3 + Details
Name: | ecd_AdjToNonPeoNeoCompFnTextBlock
Namespace Prefix: | ecd_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 3 + Details
Name: | ecd_AdjToPeoCompFnTextBlock
Namespace Prefix: | ecd_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 5 -Subparagraph ii + Details
Name: | ecd_CompActuallyPaidVsNetIncomeTextBlock
Namespace Prefix: | ecd_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 5 -Subparagraph i + Details
Name: | ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock
Namespace Prefix: | ecd_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 2 -Subparagraph iii -Sentence B -Clause 1 -Subclause ii + Details
Name: | ecd_EqtyAwrdsAdjFnTextBlock
Namespace Prefix: | ecd_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 3 + Details
Name: | ecd_NamedExecutiveOfficersFnTextBlock
Namespace Prefix: | ecd_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 2 -Subparagraph iii + Details
Name: | ecd_NonPeoNeoAvgCompActuallyPaidAmt
Namespace Prefix: | ecd_
Data Type: | xbrli:monetaryItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 2 -Subparagraph ii + Details
Name: | ecd_NonPeoNeoAvgTotalCompAmt
Namespace Prefix: | ecd_
Data Type: | xbrli:monetaryItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 2 -Subparagraph iii + Details
Name: | ecd_PeoActuallyPaidCompAmt
Namespace Prefix: | ecd_
Data Type: | xbrli:monetaryItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 3 + Details
Name: | ecd_PeoName
Namespace Prefix: | ecd_
Data Type: | xbrli:normalizedStringItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 2 -Subparagraph ii + Details
Name: | ecd_PeoTotalCompAmt
Namespace Prefix: | ecd_
Data Type: | xbrli:monetaryItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 1 + Details
Name: | ecd_PvpTable
Namespace Prefix: | ecd_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 1 + Details
Name: | ecd_PvpTableTextBlock
Namespace Prefix: | ecd_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 2 -Subparagraph iv + Details
Name: | ecd_TotalShareholderRtnAmt
Namespace Prefix: | ecd_
Data Type: | xbrli:monetaryItemType
Balance Type: | na
Period Type: | duration

X
- Definition The portion of profit or loss for the period, net of income taxes, which is attributable to the parent. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2 Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1 Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3 Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28 Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6 Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3 Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1 Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1 Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8 Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11 Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11 Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4 Reference 17: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10 Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7 Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1 Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1 Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3 Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A Reference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A Reference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A Reference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B Reference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B Reference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B Reference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B Reference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B Reference 32: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B Reference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7 Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 Reference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A Reference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1 + Details
Name: | us-gaap_NetIncomeLoss
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Details
Name: | ecd_ExecutiveCategoryAxis=ecd_PeoMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ecd_AdjToCompAxis=ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ecd_AdjToCompAxis=ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ecd_AdjToCompAxis=ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ecd_AdjToCompAxis=ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ecd_AdjToCompAxis=ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ecd_AdjToCompAxis=ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ecd_ExecutiveCategoryAxis=ecd_NonPeoNeoMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |